AVIR - Atea Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-338.4M

Cash

608.1M

Avg Qtr Burn

-22.19M

Short % of Float

2.57%

Insider Ownership

9.04%

Institutional Own.

74.22%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AT-527 (Bemnifosbuvir) Details Infectious disease, COVID-19	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bemnifosbuvir + Ruzasvir (RZR) Details Hepatitis C	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-752 Details Infectious disease, Dengue Fever	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-787 (fixed-dose combination of AT-527 & 777) Details Hepatitis C	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.